Can Allergy Shots Make Allergies Worse? The Worse Before Better Reality

Yes, temporarily — and this is a documented clinical phenomenon. Paradoxical allergy symptom worsening during SCIT build-up occurs because injections stimulate the Th2-dominant immune system before regulatory T cells and IgG4 blocking antibodies develop sufficient tolerance to balance the response (Cox et al., JACI, 2011; Akdis & Akdis, JACI, 2015). Patients may experience temporary increases in rhinitis, conjunctivitis, sneezing, and congestion — particularly during weeks 4–16 of build-up. This is NOT treatment failure and should NOT be the sole reason to discontinue. Long-term, 60–90% of patients achieve clinically meaningful improvement after completing 3–5 years of treatment.

The paradoxical worsening phase most commonly occurs during weeks 4–16 of SCIT build-up and typically begins resolving as patients approach maintenance dose — generally by months 3–6 of treatment. Individual variation exists: patients with severe baseline allergic disease, polysensitization, or who begin treatment during peak allergen season may experience a longer or more pronounced worsening period. As maintenance phase begins and injection frequency drops from weekly to monthly, many patients notice improvement in the worsening. Concurrent antihistamine and nasal corticosteroid use during build-up provides symptomatic management while tolerance develops. If worsening is severe enough to interfere with daily function, discuss a slower escalation protocol with your allergist.

Stopping allergy shots because of temporary build-up worsening is one of the most common reasons patients miss out on the treatment's long-term benefit. Studies document 10–30% premature discontinuation rates, with temporary worsening cited as a key driver — often at precisely the point when the immune transition is occurring. Before stopping, contact your allergist and describe what you're experiencing. Management strategies exist that allow continuation: slowing dose escalation, adjusting pre-medication to include daily antihistamines and nasal corticosteroids during build-up, and timing future escalations to avoid peak allergen season. Stopping is appropriate if worsening is severe and unmanageable even with these interventions — but this determination should be collaborative, not unilateral.

Precise prevalence data for paradoxical worsening is difficult to establish because it was not systematically tracked as a primary outcome in most SCIT trials — the focus has been on long-term improvement. Clinical observations suggest it occurs in a meaningful minority of patients during build-up, though 'worsening' is relative to baseline and may be perceived differently depending on seasonal timing and medication use. What is well-documented is that 10–30% of patients discontinue SCIT prematurely (adherence studies), with temporary side effects and worsening among the most cited reasons. The patients who complete 3–5 years of treatment, including those who pushed through temporary worsening, achieve the 60–90% success rate shown in systematic reviews.

Allergies seem worse at the beginning of allergy shots because the early build-up phase actively stimulates the Th2 immune pathway before regulatory mechanisms develop. Each injection delivers escalating doses of the exact allergens the immune system is sensitized to, provoking IgE production and mast cell activation in the short term. Think of it as turning up the volume on the allergic response before the immune system learns to lower the volume. Simultaneously — and less perceptibly — regulatory T cells are being induced and IgG4 antibody class switching is beginning. The regulatory response simply takes longer to reach clinical effect than the initial Th2 stimulation. Patients often don't notice the regulation beginning to work until months 3–6, when the balance tips toward tolerance.

Yes — concurrent antihistamine use during SCIT build-up is not only permitted but often recommended for patients experiencing paradoxical worsening. Daily non-sedating antihistamines (cetirizine 10mg or loratadine 10mg) measurably reduce perceived symptom worsening during build-up by blocking the histamine released during immune activation without interfering with the immunological re-education process. Nasal corticosteroid sprays provide additional mucosal protection against paradoxical nasal symptom worsening. Leukotriene inhibitors (montelukast) may also be used alongside SCIT. Using these medications during build-up is not 'cheating' or 'undermining' the treatment — they manage symptoms while tolerance develops. Discuss your current medications with your allergist before adjusting any regimen during active SCIT.

No — paradoxical worsening during SCIT build-up is temporary and not permanent. The worsening phase reflects the immune system's transitional state between Th2 dominance and Treg-mediated tolerance. As maintenance dose is reached and regulatory mechanisms mature, the amplified allergic response decreases and symptoms improve. Patients do not remain in the worsening phase permanently — the immune biology dictates a predictable trajectory toward improvement. The very rare exception: patients who experience genuine treatment failure (symptoms not improving after 12+ months at maintenance dose) are in a different category from paradoxical build-up worsening, and that situation warrants re-evaluation of extract formulation, dosing, or underlying diagnosis. But temporary build-up worsening that persists beyond 6 months is itself uncommon and warrants allergist review.